Meeting
2012 ASCO Annual Meeting
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.
Authors
Aurelius Gabriel Omlin
Section of Medicine, The Institute of Cancer Research, Sutton, UK and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Aurelius Gabriel Omlin , James F. Spicer , Debashis Sarker , David James Pinato , Roshan Agarwal , Philippe Alexandre Cassier , Chara Stavraka , Monsterrat Blanco , Aneta Suder , Suzanne Allan , Simon Heaton , Shaun Decordova , Lorna Pope , Jenny Prince , Kohei Noguchi , Keith Jones , Michiyasu Inatani , Rie Shiokawa , Udai Banerji , Sarah Patricia Blagden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
New Targets, New Technologies
Clinical Trial Registration Number
NCT01222546
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3022)
DOI
10.1200/jco.2012.30.15_suppl.3022
Abstract #
3022
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
First Author: Joaquin Mateo
Poster
2011 ASCO Annual Meeting
A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
First Author: A. J. Wagner
Poster
2019 ASCO Annual Meeting
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
First Author: Juanita Suzanne Lopez
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger